Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax in Japanese Subjects With Hematological Malignancies

NCT02265731 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02265731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02265731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax in Japanese Subjects With Hematological Malignancies
Lead sponsor
AbbVie
Phase
Phase 1/2
Overall status
Completed
Start date
September 22, 2014
Completion date
March 12, 2021
Enrollment
38 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml), chronic lymphocytic leukemia (cll), multiple myeloma (mm), non-hodgkin lymphoma (nhl), small lymphocytic lymphoma (sll)